Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Intellia Thera CS (NTLA)

Intellia Thera CS (NTLA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 981,358
  • Shares Outstanding, K 51,380
  • Annual Sales, $ 43,100 K
  • Annual Income, $ -99,530 K
  • 60-Month Beta 1.63
  • Price/Sales 25.02
  • Price/Cash Flow N/A
  • Price/Book 4.35

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.71
  • Number of Estimates 7
  • High Estimate -0.54
  • Low Estimate -0.84
  • Prior Year -0.56
  • Growth Rate Est. (year over year) -26.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.32 +44.89%
on 05/01/20
21.63 -17.48%
on 05/26/20
+2.87 (+19.16%)
since 04/27/20
3-Month
9.18 +94.44%
on 03/16/20
21.63 -17.48%
on 05/26/20
+6.24 (+53.75%)
since 02/27/20
52-Week
9.18 +94.44%
on 03/16/20
21.63 -17.48%
on 05/26/20
+3.00 (+20.20%)
since 05/24/19

Most Recent Stories

More News
Intellia Therapeutics Inc (NTLA) Reports Q1 Loss, Misses Revenue Estimates

Intellia Therapeutics Inc (NTLA) delivered earnings and revenue surprises of -61.54% and -46.14%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?...

NTLA : 17.85 (-6.54%)
NASDAQ Jumps Over 1% as Tech Sparks Late Rally

NASDAQ Jumps Over 1% as Tech Sparks Late Rally

BNFT : 12.72 (+3.41%)
HLIT : 5.86 (+3.90%)
ZYXI : 18.45 (-6.15%)
DPZ : 373.97 (+3.83%)
SPOT : 185.95 (-2.64%)
VIRT : 22.18 (+1.51%)
CLX : 200.00 (+1.46%)
CNX : 10.29 (-0.29%)
YUMC : 45.09 (unch)
STNG : 19.38 (+6.13%)
EDIT : 27.86 (+1.64%)
NTLA : 17.85 (-6.54%)
BLUE : 61.67 (-3.50%)
AMZN : 2,410.39 (-0.47%)
AAPL : 318.11 (+0.44%)
NFLX : 419.89 (+1.23%)
MSFT : 181.81 (+0.13%)
DIS : 121.53 (+0.48%)
LYFT : 33.75 (+3.94%)
UBER : 34.88 (+0.93%)
GRUB : 55.36 (-3.34%)
SQ : 81.02 (+0.28%)
BMY : 60.40 (+0.13%)
HLT : 83.15 (+1.79%)
FDA Accepts Investigational New Drug Application for CRISPR/Cas9-Based Sickle Cell Disease Therapeutic Candidate Developed Under Collaboration with Intellia Therapeutics

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced that the U.S. Food...

NVS : 84.45 (-0.71%)
NTLA : 17.85 (-6.54%)
Horrible Week Finally Comes to an End

Horrible Week Finally Comes to an End

TQQQ : 80.00 (+1.41%)
CURE : 55.62 (+3.06%)
SGMO : 11.44 (+4.62%)
TTD : 294.23 (-1.69%)
JPM : 101.37 (+5.79%)
ACCO : 6.63 (+8.87%)
NTLA : 17.85 (-6.54%)
GH : 87.73 (-1.47%)
CRSP : 63.93 (-3.63%)
Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates

Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -5.56% and 14.56%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the...

NTLA : 17.85 (-6.54%)
Intellia (NTLA) to Report Q4 Earnings: What's in Store?

Intellia (NTLA) is likely to provide an update on the IND application for its lead candidate NTLA-2001, currently being developed to address transthyretin amyloidosis.

NVS : 84.45 (-0.71%)
SAGE : 37.67 (-3.56%)
CLVS : 6.88 (unch)
NTLA : 17.85 (-6.54%)
Back from the Weekend and Back to New Highs

Back from the Weekend and Back to New Highs

SAVE : 13.90 (+12.92%)
DKS : 36.46 (+5.68%)
BBY : 79.08 (-0.49%)
ADNT : 18.18 (+3.71%)
AL : 30.40 (+6.59%)
MTW : 10.40 (+8.67%)
CAE : 15.53 (+8.68%)
OLED : 153.57 (+5.57%)
NTLA : 17.85 (-6.54%)
CRSP : 63.93 (-3.63%)
EDIT : 27.86 (+1.64%)
Implied Volatility Surging for Intellia (NTLA) Stock Options

Investors need to pay close attention to Intellia (NTLA) stock based on the movements in the options market lately.

NTLA : 17.85 (-6.54%)
Has Intellia Therapeutics (NTLA) Outpaced Other Medical Stocks This Year?

Is (NTLA) Outperforming Other Medical Stocks This Year?

NTLA : 17.85 (-6.54%)
Gene Therapy the Next Best Thing: Here's Why (Revised)

Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.

NTLA : 17.85 (-6.54%)
VRTX : 278.51 (+4.51%)
QURE : 65.59 (+2.40%)
MGTX : 15.97 (+0.63%)
PIRS : 3.40 (+3.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Trade NTLA with:

Business Summary

Intellia Therapeutics is a leading genome editing company, focused on developing therapeutics utilizing a biological tool known as CRISPR-Cas9 system. It believes the CRISPR-Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with...

See More

Key Turning Points

2nd Resistance Point 20.89
1st Resistance Point 19.37
Last Price 17.85
1st Support Level 16.80
2nd Support Level 15.75

See More

52-Week High 21.63
Last Price 17.85
Fibonacci 61.8% 16.87
Fibonacci 50% 15.41
Fibonacci 38.2% 13.94
52-Week Low 9.18

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar